Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Inclusion Criteria: * Confirmed diagnosis of congenital haemophilia A or B with a FVIII:C (Activated Coagulation Factor VIIa Clotting activity) or FIX:C (Coagulation Factor IX Clotting activity) one stage activity, respectively, at less than 5% of normal (based on medical records) plus/minus inhibitors (a positive inhibitor status defined as 0.6 Bethesda units) * Non-bleeding state (i.e. no clinical manifestation of active bleed) at the time of administration of trial product Exclusion Criteria: * Known or suspected allergy to trial product or any of its components or to related products * Known clinically relevant coagulation disorders or insufficiencies other than congenital haemophilia A or B * Platelet count below 50,000 platelets/mcL * Received any haemostatic treatment (e.g. Feiba) within the last 7 days prior to administration of trial product, except for activated recombinant human factor VII